Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven

Ruud P.M. Dings, Emily S.Van Laar, Jeremy Webber, Yan Zhang, Robert J. Griffin, Stephen J. Waters, John R. MacDonald, Kevin H. Mayo

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Combination of chemotherapeutic agents and angiogenesis inhibitors is now commonly employed in the clinic to treat cancer. Here, we used angiostatic agents anginex and 0118, in combination with the chemotherapeutic irofulven, to treat human ovarian tumor xenografts in mice. General linear mixed models were used to statistically analyze tumor growth curves. Overall, combination of a low, non-toxic dose of irofulven with either angiogenesis inhibitor was more effective at inhibiting tumor growth than any of the single agent therapies. For example, the anginex/irofulven and 0118/irofulven combinations inhibited tumor growth relative to controls by 92% (p < 0.0001) and 96% (p < 0.0001), respectively, with the 0118/irofulven combinations yielding 100% complete responses. This study suggests that combination therapy of 0118 or anginex and irofulven may be highly effective in the clinical setting.

Original languageEnglish (US)
Pages (from-to)270-280
Number of pages11
JournalCancer Letters
Volume265
Issue number2
DOIs
StatePublished - Jul 8 2008

Keywords

  • Anginex
  • Angiogenesis
  • Chemotherapy
  • Galectin-1
  • Irofulven

Fingerprint Dive into the research topics of 'Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven'. Together they form a unique fingerprint.

Cite this